School of Medicine

Wayne State University School of Medicine

Michael Cher






Michael Cher, M.D.
Professor and Chair, Department of Urology
Director of Urologic Oncology - Wayne State University School of Medicine
Chief of Urology - The Barbara Ann Karmanos Cancer Institute
Department of Urology
4201 St. Antoine – 7C UHC
Detroit, MI 48201

Clinical Interests: Minimally Invasive Approaches to Cancer Treatment
I am particularly interested in minimally invasive treatments for prostate cancer and kidney cancer. For prostate cancer, these approaches include robotic-assisted laparoscopic radical prostatectomy, targeted cryoablation of the prostate, focal cryoablation of the prostate, and radioactive seed implantation to the prostate (brachytherapy). For kidney cancer, these approaches include laparoscopic radical nephrectomy and nephroureterectomy, laparoscopic partial nephrectomy, and laparoscopic cryoablation of renal tumors. All of these approaches offer cancer destruction/removal, quick recovery, limited damage to normal tissues, and few side effects.

Urologic Oncology
I also specialize in all other aspects of urologic oncology including cancer of the adrenal gland, kidney cancer, ureteral cancer, bladder cancer, urethral cancer, testis cancer, and penile cancer. My goal is to provide individualized cancer treatments to all patients. In making treatment decisions, it is important to take into account not only the disease stage and tumor grade, but also many other factors such as overall patient health and the particular advantages and disadvantages of various treatment options and procedures. I strive to offer all of the available state-of-the-art treatment options for the various cancers and feel it is critical to involve the patient in the decision-making process.

Multi-Disciplinary Urologic Oncology
Through my work in The Barbara Ann Karmanos Cancer Institute, I also provide patients with the ability to participate in newly developed, multi-disciplinary treatment plans. This team approach often involves several different types of cancer specialists and combinations of different treatments when appropriate. We work very closely with Radiation Oncologists, Medical Oncologists, Pathologists, and Radiologists from the Karmanos Cancer Institute to develop these multi-disciplinary plans.

Special Research Interests
We have a well-funded active basic science research program in the biology of prostate cancer metastasis. Our laboratory is actively involved in determining the biological factors responsible for prostate cancer metastasis to bone marrow because the bone marrow is the most common location for distant spread of prostate cancer. We developed a new experimental model called "SCID-human model of human prostate cancer metastasis to human bone." This animal model has allowed us to investigate many of the biological factors involved in human prostate cancer cells interacting with the human bone microenvironment. In collaboration with other researchers at Wayne State University School of Medicine and The Barbara Ann Karmanos Cancer Institute, we have now published over 30 papers in this area of research. Many of our findings have become the basis for clinical trials in patients.

Selected Publications:

Mainetti LE, Zhe X, Diedrich J, Saliganan AD, Cho WJ, Cher ML, Heath E, Fridman R, Kim HR, Bonfil RD. Bone-induced c-kit expression in prostate cancer: A driver of intraosseous tumor growth. Int J Cancer. 2015;136:11-20.

Veenstra JJ, Gibson HM, Littrup PJ, Reyes JD, Cher ML, Takashima A, Wei WZ. Cryotherapy with Concurrent CpG Oligonucleotide Treatment Controls Local Tumor Recurrence and Modulates HER2/neu Immunity. Cancer Res. 2014;74:5409-20.

Singareddy R, Semaan L, Conley-Lacomb MK, St John J, Powell K, Iyer M, Smith D, Heilbrun LK, Shi D, Sakr W, Cher ML, Chinni SR. Transcriptional regulation of CXCR4 in prostate cancer: significance of TMPRSS2-ERG fusions. Mol Cancer Res. 2013;11:1349-61

Conley-Lacomb MK, Saliganan A, Kandagatla P, Chen YQ, Cher ML, Chinni SR. PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling. Mol Cancer. 2013;12:85.

Kong D, Heath E, Chen W, Cher ML, Powell I, Heilbrun L, Li Y, Ali S, Sethi S, Hassan O, Hwang C, Gupta N, Chitale D, Sakr WA, Menon M, Sarkar FH. Loss of let-7 up-regulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIM. PLoS One. 2012;7:e33729.

Kong D, Heath E, Chen W, Cher M, Powell I, Heilbrun L, Li Y, Ali S, Sethi S, Hassan O, Hwang C, Gupta N, Chitale D, Sakr WA, Menon M, Sarkar FH. Epigenetic silencing of miR-34a in human prostate cancer cells and tumor tissue specimens can be reversed by BR-DIM treatment. Am J Transl Res. 2012;4:14-23.

Najy AJ, Jung YS, Won JJ, Conley-LaComb MK, Saliganan A, Kim CJ, Heath E, Cher ML, Bonfil RD, Kim HR. Cediranib inhibits both the intraosseous growth of PDGF D-positive prostate cancer cells and the associated bone reaction. Prostate. 2012;72:1328-38.

Conley-LaComb MK, Huang W, Wang S, Shi D, Jung YS, Najy A, Fridman R, Bonfil RD, Cher ML, Chen YQ, Kim HR. PTEN regulates PDGF ligand switch for β-PDGFR signaling in prostate cancer. Am J Pathol. 2012;180:1017-27.

Education and Training
BS in Chemistry (1982): Stanford, Palo Alto, California
MD (1986): Washington University School of Medicine, St. Louis, Missouri
Internship/Residency in General Surgery (1986-1988): University of Texas Southwestern Medical Center, Dallas, Texas
Urology Residency (1988-1992): University of Texas Southwestern Medical Center, Dallas, Texas
Urologic Oncology Fellowship (1992-1995): University of California School of Medicine, California

More on Dr. Cher's SoM webpage